Growth hormone/insulin-like growth factor I axis in neurodegenerative diseases

Journal of Endocrinological Investigation

Volumn 33, Issue 8, 2010, Pages 587-591

  Gasperi, M ^a   Castellano, A E ^b  

^a UNIVERSITY OF MOLISE   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

GH; IGF I; Neurodegenerative diseases

Indexed keywords

GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; RILUZOLE; SOMATOMEDIN C;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATROPHY; CLINICAL TRIAL; DRUG MEGADOSE; GROWTH HORMONE DEFICIENCY; HUMAN; NERVE DEGENERATION; PARKINSON DISEASE; PATHOGENESIS; SHORT SURVEY;

EID: 78049377300     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03346653     Document Type: Short Survey

References (44)

1. Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect 2005, 113: 1250-6.
2. Yamawaki M, Kusumi M, Kowa H, Nakashima K. Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century. Neuroepidemiology 2009, 32: 263-9.
3. Puglielli L. Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is IGFI-R the common culprit? Neurobiol Aging 2008, 29: 795-811.
4. Adams RD, Victor M. Principle of Neurology. 3rd ed. New York: McGraw Hill. 1985, 859-901.
5. Rogaeva E, Kawarai T, George-Hyslop PS. Genetic complexity of Alzheimer's disease: successes and challenges. J Alzheimers Dis 2006, 9: 381-7.
6. Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat 2007, 28: 641-53.
7. Rothstein JD. Current hypotheses for underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009, 65: S3-9.
8. Seelaar H, Kamphorst W, Rosso SM, et al. Distinct genetic forms of frontotemporal dementia. Neurology 2008, 71: 1216-7.
9. Winklhofer KF, Tatzeit J, Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 2008, 27: 336-49.
10. Hachiya NS, Kozuka Y, Kaneko K. Mechanical stress and formation of protein aggregates in neurodegenerative disorders. Med Hypotheses 2008, 70: 1034-7. (Pubitemid 351400690)
11. Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R. Inflammation in Parkinson's disease and other neurodegenerative diseases: causes and therapeutic implications. Curr Pharm Des 2007, 13: 1925-8.
12. Iqbal K, Alonso Adel C, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005, 1739: 198-210.
13. Gasparini L, Terni B, Spillantini MG. Frontotemporal dementia with tau pathology. Neurodegener Dis 2007, 4: 236-53.
14. Takeda A, Hasegawa T, Matsuzaki-Kobayashi M. Mechanism of neural death in synucleinopathy. J Biomed Biotechnol 2006, 2006: 19365.
15. Williams AJ, Paulson HL. Polyglutamine neurodegenertaion: protein misfolding revisited. Trends Neurosci 2008, 31: 521-8.
16. Sakudo A, Ikuta K. Prion protein functions and dysfunction in prion diseases. Curr Med Chem 2009, 16: 380-9.
17. Sonntag WE, Bennett C, Ingram R, et al. Growth hormon and IGF-I modulate local cerebral glucose utilization and ATP levels in model of adult-onset growth hormone deficiency. Am J Physiol Endocrinol Metab 2006, 291: E604-10.
18. Isgaard J, Aberg D, Nilsson M. Protective and regenerative effects of the GH/IGF-I axis on the brain. Minerva Endocrinol 2007, 32: 103-13.
19. Dik MG, Pluijm SMF, Jonker C, Deeg DJ, Lomecky MZ, Lips P. Insuline-like growth factor-I (IGF-I) and cognitive decline in older persons. Neurobiol Aging 2003, 24: 573-81.
20. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reduction in acetylcholine. J Alzheimers Dis 2005, 8: 247-68. (Pubitemid 43312053)
21. Watanabe T, Miyazaki A, Katagiri T, et al. relationship between serum insulin-like growth fartor-1 levels and Alzheimer's disease and vascular dementia. J Am Geriatr Soc 2005, 53: 1748-53.
22. Gomez JM, Aguilar M, Soler J. Growth hormone and thyrotropin hormone secretion in Alzheimer' disease. J Nutr Health Aging 2000, 4: 229-32.
23. Gómez IM, Aguilar M, Navarro MA, Ortolà J, Soler J. GH response to GH-releasing hormone (GHRH) in Alzheimer and vascular dementia. Relation with somatostatin cerebrospinal levels. Ann Endocrinol (Paris) 1996, 57: 107-10.
24. Pellecchia MT, Pivonello R, Salvatore E, et al. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia. Clin Endocrinol (Oxf) 2005, 62: 428-33. (Pubitemid 40503369)
25. Morselli LL, Bongioanni P, Genovesi M, et al. Growth hormone secretion is impaired in amyotrophic lateral sclerosis. Clin Endocrinol (Oxf) 2006, 65: 385-8.
26. Morselli LL, Bongioanni P, Genovesi M et al. Impairment of GH secretion in amyotrophic lateral sclerosis is not affected by riluzole treatment. J Endocrinol Invest 2007, 30: 767-70. (Pubitemid 350238203)
27. Schneider HJ, Pagotto U, Stalla GK. Central effect of the somatotropic system. Eur J Endocrinol 2003, 149: 377-92.
28. Skuse D, Lawrence K, Tang J. Measuring social-cognitive functions in children with somatotropic axis dysfunction. Horm Res 2005, 64 (Suppl 3): 73-82.
29. Fernandez S, Fernandez AM, Lopez-Lopez C, Torres-Aleman I. Emerging roles of insulin-like growth factor-I in the adult brain. Growth Horm IGF Res 2007, 17: 89-95.
30. Vaynman S, Ying Z, Gomez-Pinilla F. Interplay between brain-derived neurotrophic factor and signal transduction modulators in the regulation of the effects of exercise on synaptic plasticity: Neuroscience 2003, 122: 647-57.
31. Arwert LI, Deijen JB, Drent ML. The relationship between insulin-like growth factor-l levels and cognition in healthy elderly: a meta-analysis. Growth Horm IGF Res 2005, 15: 416-22.
32. Aleman A, de Vries WR, de Haan EH, Verhaar HJ, Samson MM, Koppeschaar HP. Age-sensitive cognitive function, growth hormon and insulin-like growth factor-1 plasma levels in healthy older men. Neuropsycobiology 2000, 41: 73-8. (Pubitemid 30058127)
33. Volpi R, Caffarra P, Scaglioni A et al. Defective 5-HT-receptor-mediated neurotrasmission in the control of growth hormone secretion in Parknson's disease. Neuropsychobiology 1997, 33: 79-86.
34. Kiss J, Csaba Z, Csáki A, Halász B. Glutamatergic innervation of growth hormone-releasing containing neurons in the hypothalamic arcuate nucleus nad somatostatin-containin neurons in the anterior periventricular nucleus of the rat. Brain Res Bull 2006, 70: 278-88. (Pubitemid 44486553)
35. Revill P, Moral MA, Prous JR. Impaired insulin signaling and the pathogenesis of Alzheimer's disease. Drugs today (Barc) 2006, 42: 785-90. (Pubitemid 46255495)
36. Adlerz L, Holback S, Multhaup G, Iverfeldt K. IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways. J Biol Chem 2007, 282: 10203-9.
37. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008, 2: 1101-13.
38. Reger MA, Watson GS, Frey WH, et al. Effects of intranasal insulin on cognition in memory-impaired old adults:modulation by APOE genotype. Neurobiol Aging 2006, 27: 451-8.
39. Landreth G. PPRAgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease. Exp Neurol 2006, 199: 245-8.
40. Holmberg B, Johansson JO, Poewe W, et al; Growth-Hormone MSA Study Group; European MSA Study Group. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 2007, 22: 1138-44.
41. Torres-Aleman I, Barrios V, Berciano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology 1998, 50: 772-6.
42. Lai EC, Felice KJ, Festoff BW, et al Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I study group. Neurology 1997, 49, 6: 1621-30.
43. Mitchell JD, Wokke JHJ, Borasio GD. Recombinant human insulin-like growth factor (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2007, 4: CD002064.
44. Smith RA, Melmed S, Sherman B, Frane J, Munsat TL, Festoff BW. Recombinant growth hormone treatement of amyotrophic lateral sclerosis. Muscle Nerve 1993, 16: 624-33. (Pubitemid 23157334)